Texas Tissue Bank License Requirements for Biologics

In Texas, facilities that collect, process, store, or distribute human cells, tissues, and cellular and tissue-based products (HCT/Ps) must comply with Texas Department of State Health Services (DSHS) Tissue Bank Licensing regulations under Texas Health and Safety Code Chapter 144 alongside federal FDA 21 CFR 1271 standards. Medical practices administering pre-packaged tissue allografts for immediate clinical application generally fulfill compliance requirements by sourcing exclusively from DSHS-licensed tissue banks and maintaining validated chain-of-custody storage logs.

Navigating state and federal compliance for human cells and tissue-based products is a vital operational requirement for clinical practices offering regenerative protocols. As interest in biologics such as amniotic tissue, Wharton's Jelly, cord blood derivatives, and exosomes expands across specialties, practice administrators and medical directors must establish clear protocols to ensure patient safety, legal compliance, and seamless chain-of-custody workflows.

Understanding the Regulatory Framework: FDA 21 CFR 1271 and Texas DSHS

Handling cellular tissue products involves two distinct levels of regulatory oversight: federal rules governed by the U.S. Food and Drug Administration (FDA) and state regulations administered by the Texas Department of State Health Services (DSHS).

Federal Level: FDA 21 CFR Part 1271

The FDA regulates human cells, tissues, and cellular and tissue-based products under 21 CFR Part 1271. Products are generally categorized into two distinct regulatory pathways:

• Section 361 HCT/Ps: Products that are minimally manipulated, intended for homologous use, and do not involve systemic effects or reliance on the metabolic activity of living cells. These products do not require pre-market approval but must be registered with the FDA and comply with Current Good Tissue Practice (cGTP).
• Section 351 Products: Biologics that undergo more than minimal manipulation or are designated for non-homologous use. These are regulated as drugs, biological products, or medical devices, requiring Investigational New Drug (IND) applications or Biologics License Applications (BLA).

State Level: Texas DSHS Tissue Bank Licensing

Under Texas Health and Safety Code Chapter 144, Texas mandates that any entity operating a tissue bank within the state—or offering tissue for distribution within Texas—must obtain a Texas Tissue Bank License from the DSHS. The state defines a tissue bank as any facility that stores, processes, keeps, or distributes human tissue for transplantation, therapy, or research.

For a medical practice, the key distinction lies between operating a tissue bank and acting as an end-user clinical facility. Practices that simply purchase finished, single-use, sterile allografts from a licensed vendor and store them strictly for clinical administration to their own patients typically do not require an independent tissue bank license. However, if a practice processes tissue, holds inventory for redistribution to other practices, or functions as a central tissue storage depot, DSHS licensing becomes mandatory.

Operational vs. Clinical Responsibilities in Biologics Compliance

Implementing tissue protocols requires coordination between the practice management team and the clinical staff. Each role holds distinct compliance responsibilities.

Operational Perspective: Practice Managers and Procurement

Practice managers handle the administrative infrastructure required to protect the practice from regulatory liability and operational loss:

• Vendor Licensure Verification: Before issuing a purchase order for HCT/P products, administrators must confirm that both the primary tissue manufacturer and the regional distributor possess active Texas DSHS Tissue Bank Licenses and valid FDA registrations.
• Cold-Chain Oversight: Biologics require strict temperature control, ranging from standard refrigeration (2°C to 8°C) to ultra-low temperature cryopreservation (-80°C or nitrogen vapor phase). Operational teams must invest in medical-grade storage units with continuous temperature logging, battery backups, and automated alarm systems.
• Inventory Tracking and Lot Traceability: Practice administrators must maintain logs connecting manufacturer lot numbers to specific patient charts. In the event of a vendor product recall, the practice must be capable of identifying affected patients within hours.

Clinical Perspective: Physicians and Treating Clinicians

Physicians evaluating tissue options focus on safety, biological integrity, and compliant patient care:

• Homologous Use Determination: Regenerative medicine doctors and pain management doctors must ensure that the selected tissue product is applied in a manner consistent with its structural function in the donor. Using an allograft for non-homologous indications can reclassify a Section 361 product into an unapproved Section 351 drug.
• Donor Screening and Testing Verification: Clinicians must verify that every tissue package includes a complete Certificate of Analysis (CoA) and Summary of Records confirming negative screening results for infectious agents (such as HIV, Hepatitis B, and Hepatitis C) in accordance with FDA cGTP requirements.
• Informed Consent Protocols: Clinical staff must inform patients regarding the origin of human tissue allografts, detailing donor screening standards, processing methods, and expected structural capabilities.

Vendor Evaluation Checklist for Texas Medical Practices

When evaluating supply partners for cellular products and allografts, practice administrators should use the following checklist during procurement review:

1. Texas DSHS License Verification: Obtain a copy of the supplier's active Texas Tissue Bank License. Ensure the license number is valid and currently listed on the state registry.
2. FDA Establishment Registration: Confirm the manufacturer’s FDA Form 3356 registration status via the FDA Human Cell and Tissue Establishment Registration (HCTERS) database.
3. Certificate of Analysis (CoA) Delivery: Ensure every single tissue lot is accompanied by a CoA documenting sterility testing, endotoxin levels, microbial testing, and donor eligibility confirmation.
4. Cold-Chain Validation Protocols: Verify that the vendor ships tissue using validated, insulated cold-chain transport packaging equipped with real-time temperature indicators.
5. Chain of Custody Documentation: Require serial-numbered packing slips that match product vial numbers to streamline practice inventory logging and audit readiness.
6. Regulatory Support and Compliance Documentation: Partner with established distributors who provide standard operating procedure (SOP) templates for local tissue receiving and handling.

What This Means for Your Practice

Maintaining full compliance with Texas tissue handling regulations does not require burdensome administrative overhead if structured correctly. Practices can protect their licensure and clinical reputation by executing three immediate operational steps:

• Audit Current Biologics Suppliers: Audit all existing suppliers of amniotic tissue, fluid, exosomes, or donor allografts. Request current copies of their Texas DSHS Tissue Bank License and FDA registration. Store these in your compliance binder.
• Upgrade Local Temperature Monitoring: Transition away from residential-grade refrigeration or freezer units. Ensure all tissue storage equipment utilizes continuous electronic monitoring and daily manual verification logs.
• Standardize Patient-to-Lot Matching: Establish a strict workflow within your Electronic Health Records (EHR) system where the tissue lot number, expiration date, and manufacturer name are recorded directly in the procedure notes for every administration.

By establishing strong vendor vetting procedures and strict cold-chain logging, practices can confidently offer advanced biologics while remaining fully compliant with state and federal regulations.

To learn more about compliant biologics sourcing, tissue documentation, or device integration for your facility, review our comprehensive clinical resource library at DRS or reach out directly to our team via our contact page.